FDA
approval
· 2024-03-20
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
Summary
The FDA approved a supplemental application from Lannett Company for a buprenorphine/naloxone product, expanding access to a generic treatment option for opioid…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)